Drugs / hu5B1-TCO
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05737615 | Feb 2023 → Feb 2026 | pancreatic ductal adenocarcinoma | Memorial Sloan Kettering Cancer Center | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hu5B1-TCO | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05737615 ↗ |
| Modality | Protein / enzyme biologic | “a Trans-Cyclooctene-Modified Humanized 5B1 Immunoconjugate (hu5B1-TCO)” NCT05737615 ↗ |
| Route | Intravenous | “a single slow infusion of hu5B1-TCO will be administered intravenously” NCT05737615 ↗ |